ERgot mesylates for Alzheimer's disease: A year-long double-blind trial of 3 mg VS 12 mg daily

M. A. Jenike, Marilyn Albert, L. Baer, J. Gunther, C. Corvino

Research output: Contribution to journalArticle

Abstract

Of 25 patients who entered a year-long doubl-blind comparison study of high (12 mg/day) versus low (3 mg/day) dosages of ergot mesylated (Hydergine), 17 completed the full yera of study and no patiens suffered problematic side-effects. On a number of complex tests of memory function, there was no difference between the patients receiving low-dose versus high-dose Hydergine. There were also no significant between-group differences in recognition memory, incidental memory, naming ability, figure drawing, mood or other psychiatric symptoms. These data confirm that Hydergine is safe and that trials in a low dosage range may suffice.

Original languageEnglish (US)
Pages (from-to)375-380
Number of pages6
JournalInternational Journal of Geriatric Psychiatry
Volume5
Issue number6
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Ergoloid Mesylates
Mesylates
Alzheimer Disease
Aptitude
Psychiatry

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

ERgot mesylates for Alzheimer's disease : A year-long double-blind trial of 3 mg VS 12 mg daily. / Jenike, M. A.; Albert, Marilyn; Baer, L.; Gunther, J.; Corvino, C.

In: International Journal of Geriatric Psychiatry, Vol. 5, No. 6, 1990, p. 375-380.

Research output: Contribution to journalArticle

@article{481e85b34c2048d080a5be93c406bc25,
title = "ERgot mesylates for Alzheimer's disease: A year-long double-blind trial of 3 mg VS 12 mg daily",
abstract = "Of 25 patients who entered a year-long doubl-blind comparison study of high (12 mg/day) versus low (3 mg/day) dosages of ergot mesylated (Hydergine), 17 completed the full yera of study and no patiens suffered problematic side-effects. On a number of complex tests of memory function, there was no difference between the patients receiving low-dose versus high-dose Hydergine. There were also no significant between-group differences in recognition memory, incidental memory, naming ability, figure drawing, mood or other psychiatric symptoms. These data confirm that Hydergine is safe and that trials in a low dosage range may suffice.",
author = "Jenike, {M. A.} and Marilyn Albert and L. Baer and J. Gunther and C. Corvino",
year = "1990",
doi = "10.1002/gps.930050605",
language = "English (US)",
volume = "5",
pages = "375--380",
journal = "International Journal of Geriatric Psychiatry",
issn = "0885-6230",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - ERgot mesylates for Alzheimer's disease

T2 - A year-long double-blind trial of 3 mg VS 12 mg daily

AU - Jenike, M. A.

AU - Albert, Marilyn

AU - Baer, L.

AU - Gunther, J.

AU - Corvino, C.

PY - 1990

Y1 - 1990

N2 - Of 25 patients who entered a year-long doubl-blind comparison study of high (12 mg/day) versus low (3 mg/day) dosages of ergot mesylated (Hydergine), 17 completed the full yera of study and no patiens suffered problematic side-effects. On a number of complex tests of memory function, there was no difference between the patients receiving low-dose versus high-dose Hydergine. There were also no significant between-group differences in recognition memory, incidental memory, naming ability, figure drawing, mood or other psychiatric symptoms. These data confirm that Hydergine is safe and that trials in a low dosage range may suffice.

AB - Of 25 patients who entered a year-long doubl-blind comparison study of high (12 mg/day) versus low (3 mg/day) dosages of ergot mesylated (Hydergine), 17 completed the full yera of study and no patiens suffered problematic side-effects. On a number of complex tests of memory function, there was no difference between the patients receiving low-dose versus high-dose Hydergine. There were also no significant between-group differences in recognition memory, incidental memory, naming ability, figure drawing, mood or other psychiatric symptoms. These data confirm that Hydergine is safe and that trials in a low dosage range may suffice.

UR - http://www.scopus.com/inward/record.url?scp=0025204662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025204662&partnerID=8YFLogxK

U2 - 10.1002/gps.930050605

DO - 10.1002/gps.930050605

M3 - Article

AN - SCOPUS:0025204662

VL - 5

SP - 375

EP - 380

JO - International Journal of Geriatric Psychiatry

JF - International Journal of Geriatric Psychiatry

SN - 0885-6230

IS - 6

ER -